Related Experiment Video
Updated: Jun 9, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Drug-implantable cardioverter-defibrillator interactions
Roger Beadle1, Lynne Williams, Hoong Sern Lim
1School of Medicine and Dentistry, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, Scotland AB25 2ZD, UK. rogerbeadle@hotmail.com
Abstract:
Antiarrhythmic drugs are commonly used synergistically with implantable cardioverter defibrillators in the management of ventricular and supraventricular arrhythmias. However, these drugs may directly or indirectly interact with device function. In addition, expanding indications for implantable cardioverter defibrillators, particularly in patients with multiple comorbidities, further increases the potential for drug-device interactions. These potential drug-device interactions are summarized in this article.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Pharmacokinetics: Drug–Drug Interactions
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure VI: Adjunct Therapies
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
